The speakers will discuss how highly sensitive single-cell DNA sequencing (scDNA-seq) on the Tapestri Platform accelerates CGT workflows.
TORONTO (PRWEB) May 18, 2021
Cell and gene therapies (CGTs) hold promise for the treatment of a variety of diseases including cancer and rare genetic disorders such as sickle-cell disease. Many of these therapies involve the genetic engineering of cells in order to insert exogenous sequences or alter existing genes. After the cells are altered, they are introduced into the patient where they either replace dysfunctional cells or provide a desired immune response. The use of engineered cells for human therapies requires sensitive and robust characterization of genomic manipulations, which are typically achieved through viral transduction or the use of gene editors, such as CRISPR.
All methods of genetic engineering yield cell populations with genetic heterogeneity. For instance, there may be cell-to-cell variability in transduction efficiency and copy number (for viruses), or for on- and off-target editing efficiencies (for gene editors). Because unintended genomic alterations may have consequences to the efficacy and safety of therapeutic agents, it is imperative that engineered cells be characterized with a high degree of accuracy and sensitivity. Measuring genomic manipulations at a single-cell level provides the most robust characterization of CGT products.
The speakers will discuss how highly sensitive single-cell DNA sequencing (scDNA-seq) on the Tapestri Platform accelerates CGT workflows. They will discuss the advantages of Tapestri for the quantification of cell-specific alterations achieved through viral vectors and gene editors, and contrast this approach to conventional multi-assay processes. They will also explain how integrating Tapestri into the CGT pipeline —from development to manufacturing and release testing — consolidates workflows and accelerates bringing breakthrough therapies to market.
For more information, or to register for this event, visit A New Single-Cell Sequencing and Analysis Platform to Accelerate Cell and Gene Therapy Pipelines.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.